ArticleClinical and vaccine immunology : CVI2016
Shigella Vaccine Development: Finding the Path of Least Resistance.
Article in Clinical and vaccine immunology : CVI, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- A PentavalentVaccines · 2023Article
- Immunization of Rabbits with a QuadrivalentmSphere · 2022Article
- Duration of Postdiarrheal Enteric Pathogen Carriage in Young Children in Low-resource Settings.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Identification and evaluation of novel vaccine candidates against Shigella flexneri through reverse vaccinology approach.Applied microbiology and biotechnology · 2021Article
- Establishment of a Controlled Human Infection Model with a Lyophilized Strain of Shigella sonnei 53G.mSphere · 2020Article
- Increasing the Affinity of an O-Antigen Polysaccharide Binding Site in Shigella flexneri Bacteriophage Sf6 Tailspike Protein.Chemistry (Weinheim an der Bergstrasse, Germany) · 2020Article
- SipD and IpaD induce a cross-protection against Shigella and Salmonella infections.PLoS neglected tropical diseases · 2020Article
- Challenges of Developing Novel Vaccines With Particular Global Health Importance.Frontiers in immunology · 2020Review
- Characterization and immunogenicity of a Shigella flexneri 2a O-antigen bioconjugate vaccine candidate.Glycobiology · 2019Article
- Review
- Article
- A Phase 2a Randomized Study to Evaluate the Safety and Immunogenicity of the 1790GAHB Generalized Modules for Membrane Antigen Vaccine againstFrontiers in immunology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Shigella spp. represent the second most common etiologic pathogen causing childhood diarrhea in developing countries. There are no licensed Shigella vaccines, and progress for such vaccines has been limited. In this issue of Clinical and Vaccine Immunology, Riddle and colleagues (M. S. Riddle, R. W. Kaminski, C. Di Paolo, C. K. Porter, R. L. Gutierrez, et al., Clin Vaccine Immunol 23:908-917, 2016, http://dx.doi.org/10.1128/CVI.00224-16) report results from a phase I study of a parenterally administered monovalent O-polysaccharide "bioconjugate" directed against Shigella flexneri 2a. Ultimately, the goal is to develop a broad-spectrum Shigella vaccine to address this public health concern. A parenteral Shigella vaccine capable of eliciting protection in children of developing countries would be an important tool to reach this goal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.